Search tips
Search criteria 


Logo of aacPermissionsJournals.ASM.orgJournalAAC ArticleJournal InfoAuthorsReviewers
Antimicrob Agents Chemother. 2017 April; 61(4): e02610-16.
Published online 2017 March 24. Prepublished online 2017 February 6. doi:  10.1128/AAC.02610-16
PMCID: PMC5365689

Importance of Clonal Complex 258 and IncFK2-like Plasmids among a Global Collection of Klebsiella pneumoniae with blaKPC


This study was designed to determine the global distribution of clonal complex (CC) 258 and IncFIIK2-like plasmids with blaKPC among 522 global Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae isolates. CC258 (i.e., ST258 [clades I and II], ST11, ST340, and ST512) and ST147 were statistically associated with IncFIIK2-like KPC-containing plasmids and may possess an epidemiological advantage over isolates that harbored non-IncF KPC-harboring plasmids.

KEYWORDS: Klebsiella pneumoniae, ST258, IncFK plasmids


The class A Klebsiella pneumoniae carbapenemase (KPC) β-lactamases have been extensively reported in K. pneumoniae (1). KPCs are present in >100 different K. pneumoniae sequence types (STs), but the KPC pandemic is primarily driven by the spread of members of clonal complex (CC) 258, namely, ST258 (clades I, II), ST11, ST340, and ST512 (1).

Several different KPC-containing plasmids (i.e., IncF, IncI2, IncX, IncA/C, IncR, and ColE1) have been identified in CC258 (2); however, the most predominant plasmid type is IncF with FIIk replicons, i.e., IncFIIK1 (FIBpKPN-like) and IncFIIK2 (FIBpKPQIL-like) (3). pKpQIL was the prototype of the IncFIIK2 group and one of the most common blaKPC-harboring plasmids, reported in Israel, the United States, the United Kingdom, Colombia, and Italy (2). pKPN-3 was the prototype of the IncFIIK1 and was not initially associated with blaKPC but was a virulence plasmid and coresident with pKpQIL within ST258 (2). In the current study, we set out to determine the presence and global distribution of CC258 among a defined population consisting of 522 KPC-producing K. pneumoniae isolates from AstraZeneca's (AZ) international surveillance study on antimicrobial resistance (2012 to 2014). We also investigated the association of IncFIIK2-like plasmids containing blaKPC with CC258 strains versus with non-CC258 strains.

The AZ global surveillance program was initiated in 2012 and includes a wide representation of microbiology laboratories among the various continents (4). Up to 100 consecutive nonselected Gram-negative aerobic and facultative bacilli from each of the participating countries/hospitals are included. All organisms are deemed clinically significant based on the criteria of the local investigators and were obtained from urinary tract, skin structure, intra-abdominal, and lower respiratory tract specimens. The countries participating in the surveillance include, in Africa, Egypt, Kenya, Nigeria, and South Africa; in Asia, China, South Korea, Taiwan, and Thailand; in Europe, Austria, Belgium, Bulgaria, Greece, Czech Republic, Denmark, France, Germany, Hungary, Italy, Macedonia, Portugal, Poland, Russia, Romania, Slovakia, Spain, Turkey, and the United Kingdom; in Latin America, Argentina, Brazil, Chile, Colombia, Mexico, Uruguay, and Venezuela; in the Middle East, Lebanon, Israel, Syria, and Kuwait; in North America, the United States; and in the South Pacific, Australia, Philippines, and Japan.

The AZ surveillance program does have some drawbacks. It only includes 100 consecutive nonselected Gram-negative aerobic and facultative bacilli from each participating country/hospital/year. It is therefore possible that the program will miss outbreaks of a particular resistance mechanism. The program is also biased toward sites that have AZ representation within that region/city/country (i.e., hospitals that can afford AZ products). Moreover, it only includes isolates from urinary tract, skin structure, intra-abdominal, and lower respiratory tract specimens. The program has some significant advantages as well. It includes a wide representation of microbiology laboratories among the various continents, although Africa and Asia are underrepresented. It only includes clinically significant bacteria and is not biased toward a certain resistance phenotype. Therefore, it provides a snapshot of the types of resistance determinants that are endemic in a specific hospital/region.

Molecular screening for blaKPC was performed on carbapenem-resistant K. pneumoniae as described previously (5). Genetic relatedness among the isolates was initially determined using pulsed-field gel electrophoresis (PFGE) (6), and the major pulsotypes (those with >10 isolates per pulsotype) also underwent multilocus sequencing typing (MLST) (7). PCR typing was used to determine the presence of blaKPCs on IncFIIK2-like types of plasmids and to identify the different Tn4401 isotypes (8, 9). Table 1 illustrates the PCR primers and the respective targets used in this study. IncFIIK2-like plasmids were identified with amplifications with all the primer sets, namely, I, II, III, IV, V, and VI.

Primers and target sizes for the characterization of IncFIIK2-like plasmids that contain blaKPC

PFGE identified four major pulsotypes among 412 isolates (79%) that were designated clusters A (n = 290), B (n = 80), C (n = 27), and D (n = 15). We also recognized three minor pulsotypes (those with <10 isolates per pulsotype) among 23 isolates (4%), designated clusters E (n = 9), F (n = 7), and G (n = 7). The remaining isolates (n = 87 [17%]) were not clonally related; i.e., they exhibited <60% similar PFGE profiles and did not show patterns similar to those from clusters A to G. MLST identified the different pulsotypes as follows: cluster A, ST258; cluster B, ST11; cluster C, ST147; cluster D, ST512; cluster E, ST189; cluster F, ST15; and cluster G, ST437. ST258 was further differentiated into clades I and II (10). The geographic distribution of the different blaKPCs, STs, and IncFIIK2-like plasmids associated with blaKPC are shown in Table 2.

Sequence types, global distribution, and presence of IncFIIK2-like plasmids among K. pneumoniae with blaKPC

K. pneumoniae ST258 is a prototype of a high-risk clone and has been largely responsible for the global spread of carbapenem resistance among the Enterobacteriaceae (11). Deleo and colleagues (10) performed whole-genome sequencing on a global collection of K. pneumoniae ST258 isolates and showed that this ST belonged to two well-defined lineages, clade I and clade II. Clade I was associated with KPC-2, and clade II was associated with KPC-3. The majority of K. pneumoniae (n = 290 [56%]) from our global collection belonged to ST258; clade I (n = 165 [32%]) was associated with blaKPC-2 on IncFIIK2-like plasmids. This clade was mostly present in Argentina and Greece and to a lesser extent in Belgium, China, Italy, Romania, and the United States (Table 2). ST258 clade II (n = 125 [24%]) was associated with blaKPC-3 on IncFIIK2-like plasmids. This clade was mainly identified in Italy and the United States and to a lesser extent in Austria, Belgium, Brazil, Chile, Colombia, Germany, Greece, Israel, Mexico, and Venezuela (Table 2). No specific association of blaKPC-2 or blaKPC-3 with IncFIIK2-like plasmids was seen (40% of KPC-2 and 54% of KPC-3 were harbored on IncFIIK2-like plasmids) (Table 2).

ST11, which is closely related to ST258, is the major ST among K. pneumoniae harboring blaKPC from Asia (especially China) (12) and Latin America (13) and sometimes contains other carbapenemases (14, 15). ST11 was the second-most-common ST in our study (n = 80 [15%]) and was associated with blaKPC-2 on IncFIIK2-like plasmids. ST11 was present in Brazil and China and to a lesser extent in Argentina, Colombia, Israel, Taiwan, the United States, and Venezuela (Table 2).

Other STs that belong to CC258 with blaKPC were reported from Colombia (ST512), Italy (ST512), Israel (ST512), Brazil (ST340, ST437), and Greece (ST340) (13). The remaining members of CC258 from our study included ST512 and ST437. ST512, mainly from Colombia, was the fourth-most-common ST (n = 15 [3%]) in our collection and was also identified in Israel, Italy, and the United States (Table 2). The ST was associated with blaKPC-3 on IncFIIK2-like plasmids. ST437 (n = 7) was identified in Brazil and did not contain IncF plasmids.

K. pneumoniae ST147 is an emerging high-risk clone that was first identified in Greece, where it has been associated with blaVIM and blaKPC (16, 17). NDM (18) and OXA-181 (6) carbapenemases have also been described in ST147 from various countries, such as Switzerland, Iraq, Canada, the United Kingdom, India, and Italy (1). ST147, mainly from Greece, was the third-most-common ST (n = 27 [5%]) in our study and was associated with blaKPC-2 on IncFIIK2-like plasmids. ST147 was also present in Argentina, Italy, Philippines, Romania, and Venezuela (Table 2).

The geographic distribution of the other minor STs was as follows: ST189 (n = 9) in Colombia and ST15 (n = 7) in Portugal (Table 2). The isolates that did not belong to major or minor STs (n = 87) showed a global distribution. The IncFII (none k2-like) plasmids (n = 141) contained Tn4401 isotypes a (66 [47%]), b (34 [24%]), and d (5 [4%]); IncFIIK2-like plasmids (n = 264) only contained isotype a.

It was recently postulated that the presence of IncF plasmids with FIIk replicons harboring blaKPC is central to the global success of CC258 and that these plasmids have contributed significantly to the evolutionary dominance of ST258 (11). Our molecular epidemiological data support this hypothesis. The majority of CC258 isolates from our study harbored IncFIIK2-like plasmids containing blaKPC, in contrast to non-CC258 STs (226/392 [58%] versus 38/130 [23%]; P < 0.0001). This is especially true for ST258 in that 188/290 plasmids [65%] with blaKPC from this ST belonged to IncFIIK2-like (Table 2). K. pneumoniae ST147 was also associated with IncF plasmids, especially IncFIIK2-like (Table 2). Our data suggest that certain successful high-risk K. pneumoniae clones (i.e., CC258 and ST147) are linked to specific narrow-host-range IncF plasmids with blaKPC, and this association may possess epidemiological advantages over other clones that carry non-IncF KPC plasmids. It is possible that the maintenance and coevolution of GC258 with IncFK2-like plasmids provide rapid and continual adaptation opportunities for this CC, providing them with the additional ability to outcompete other K. pneumoniae clones. This scenario is consistent with both the macro- and microevolutionary versions of the Red Queen hypothesis of coevolution (11). However, this might be a very simplistic view regarding the role of IncFK2-like plasmids in the success of CC258, and this CC frequently harbors non-F antimicrobial resistance plasmids (1).

This study was not designed to specifically address the epidemiological advantage attributed to IncFIIK2-like plasmids compared to other features of CC258. The IncFIIK2-like plasmids are clearly the most common KPC-containing plasmids disseminating in K. pneumoniae but are not necessarily restricted to CC258 (23% of non-CC258 STs also contained IncFIIK2-like plasmids). To the best of our knowledge, this is the first study to provide a comprehensive overview on the global distribution of different STs with blaKPC and the association of these STs with IncFIIK2-like plasmids in a defined population.


This work was supported in part by a research grant from the Calgary Laboratory Services (10015169) and National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services award number R01AI090155 (to B.K.).

J.D.D.P. previously received research funds from Merck and Astra Zeneca.


1. Pitout JD, Nordmann P, Poirel L 2015. Carbapenemase-producing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance. Antimicrob Agents Chemother 59:5873–5884. doi:.10.1128/AAC.01019-15 [PMC free article] [PubMed] [Cross Ref]
2. Chen L, Mathema B, Chavda KD, DeLeo FR, Bonomo RA, Kreiswirth BN 2014. Carbapenemase-producing Klebsiella pneumoniae: molecular and genetic decoding. Trends Microbiol 22:686–696. doi:.10.1016/j.tim.2014.09.003 [PMC free article] [PubMed] [Cross Ref]
3. Chen L, Chavda KD, Melano RG, Jacobs MR, Levi MH, Bonomo RA, Kreiswirth BN 2013. Complete sequence of a bla(KPC-2)-harboring IncFII(K1) plasmid from a Klebsiella pneumoniae sequence type 258 strain. Antimicrob Agents Chemother 57:1542–1545. doi:.10.1128/AAC.02332-12 [PMC free article] [PubMed] [Cross Ref]
4. Kazmierczak KM, Rabine S, Hackel M, McLaughlin RE, Biedenbach DJ, Bouchillon SK, Sahm DF, Bradford PA 2016. Multiyear, multinational survey of the incidence and global distribution of metallo-β-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 60:1067–1078. doi:.10.1128/AAC.02379-15 [PMC free article] [PubMed] [Cross Ref]
5. Peirano G, Bradford PA, Kazmierczak KM, Badal RE, Hackel M, Hoban DJ, Pitout JD 2014. Global incidence of carbapenemase-producing Escherichia coli ST131. Emerg Infect Dis 20:1928–1931. doi:.10.3201/eid2011.141388 [PMC free article] [PubMed] [Cross Ref]
6. Lascols C, Peirano G, Hackel M, Laupland KB, Pitout JD 2013. Surveillance and molecular epidemiology of Klebsiella pneumoniae isolates that produce carbapenemases: first report of OXA-48-like enzymes in North America. Antimicrob Agents Chemother 57:130–136. doi:.10.1128/AAC.01686-12 [PMC free article] [PubMed] [Cross Ref]
7. Diancourt L, Passet V, Verhoef J, Grimont PA, Brisse S 2005. Multilocus sequence typing of Klebsiella pneumoniae nosocomial isolates. J Clin Microbiol 43:4178–4182. doi:.10.1128/JCM.43.8.4178-4182.2005 [PMC free article] [PubMed] [Cross Ref]
8. Chen L, Chavda KD, Melano RG, Hong T, Rojtman AD, Jacobs MR, Bonomo RA, Kreiswirth BN 2014. Molecular survey of the dissemination of two blaKPC-harboring IncFIA plasmids in New Jersey and New York hospitals. Antimicrob Agents Chemother 58:2289–2294. doi:.10.1128/AAC.02749-13 [PMC free article] [PubMed] [Cross Ref]
9. Chen L, Chavda KD, Melano RG, Jacobs MR, Koll B, Hong T, Rojtman AD, Levi MH, Bonomo RA, Kreiswirth BN 2014. Comparative genomic analysis of KPC-encoding pKpQIL-like plasmids and their distribution in New Jersey and New York Hospitals. Antimicrob Agents Chemother 58:2871–2877. doi:.10.1128/AAC.00120-14 [PMC free article] [PubMed] [Cross Ref]
10. Deleo FR, Chen L, Porcella SF, Martens CA, Kobayashi SD, Porter AR, Chavda KD, Jacobs MR, Mathema B, Olsen RJ, Bonomo RA, Musser JM, Kreiswirth BN 2014. Molecular dissection of the evolution of carbapenem-resistant multilocus sequence type 258 Klebsiella pneumoniae. Proc Natl Acad Sci U S A 111:4988–4993. doi:.10.1073/pnas.1321364111 [PubMed] [Cross Ref]
11. Mathers AJ, Peirano G, Pitout JD 2015. The role of epidemic resistance plasmids and international high-risk clones in the spread of multidrug-resistant Enterobacteriaceae. Clin Microbiol Rev 28:565–591. doi:.10.1128/CMR.00116-14 [PMC free article] [PubMed] [Cross Ref]
12. Yang J, Ye L, Guo L, Zhao Q, Chen R, Luo Y, Chen Y, Tian S, Zhao J, Shen D, Han L 2013. A nosocomial outbreak of KPC-2-producing Klebsiella pneumoniae in a Chinese hospital: dissemination of ST11 and emergence of ST37, ST392 and ST395. Clin Microbiol Infect 19:E509–E515. doi:.10.1111/1469-0691.12275 [PubMed] [Cross Ref]
13. Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, Cornaglia G, Garau J, Gniadkowski M, Hayden MK, Kumarasamy K, Livermore DM, Maya JJ, Nordmann P, Patel JB, Paterson DL, Pitout J, Villegas MV, Wang H, Woodford N, Quinn JP 2013. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 13:785–796. doi:.10.1016/S1473-3099(13)70190-7 [PMC free article] [PubMed] [Cross Ref]
14. Giske CG, Froding I, Hasan CM, Turlej-Rogacka A, Toleman M, Livermore D, Woodford N, Walsh TR 2012. Diverse sequence types of Klebsiella pneumoniae contribute to the dissemination of blaNDM-1 in India, Sweden, and the United Kingdom. Antimicrob Agents Chemother 56:2735–2738. doi:.10.1128/AAC.06142-11 [PMC free article] [PubMed] [Cross Ref]
15. Williamson DA, Sidjabat HE, Freeman JT, Roberts SA, Silvey A, Woodhouse R, Mowat E, Dyet K, Paterson DL, Blackmore T, Burns A, Heffernan H 2012. Identification and molecular characterisation of New Delhi metallo-β-lactamase-1 (NDM-1)- and NDM-6-producing Enterobacteriaceae from New Zealand hospitals. Int J Antimicrob Agents 39:529–533. doi:.10.1016/j.ijantimicag.2012.02.017 [PubMed] [Cross Ref]
16. Papagiannitsis CC, Kotsakis SD, Petinaki E, Vatopoulos AC, Tzelepi E, Miriagou V, Tzouvelekis LS 2011. Characterization of metallo-beta-lactamase VIM-27, an A57S mutant of VIM-1 associated with Klebsiella pneumoniae ST147. Antimicrob Agents Chemother 55:3570–3572. doi:.10.1128/AAC.00238-11 [PMC free article] [PubMed] [Cross Ref]
17. Giakkoupi P, Papagiannitsis CC, Miriagou V, Pappa O, Polemis M, Tryfinopoulou K, Tzouvelekis LS, Vatopoulos AC 2011. An update of the evolving epidemic of blaKPC-2-carrying Klebsiella pneumoniae in Greece (2009-10). J Antimicrob Chemother 66:1510–1513. doi:.10.1093/jac/dkr166 [PubMed] [Cross Ref]
18. Peirano G, Pillai DR, Pitondo-Silva A, Richardson D, Pitout JD 2011. The characteristics of NDM-producing Klebsiella pneumoniae from Canada. Diagn Microbiol Infect Dis 71:106–109. doi:.10.1016/j.diagmicrobio.2011.06.013 [PubMed] [Cross Ref]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)